MY139645A - Vanilloid receptor ligands and their use in treatments - Google Patents
Vanilloid receptor ligands and their use in treatmentsInfo
- Publication number
- MY139645A MY139645A MYPI20050501A MYPI20050501A MY139645A MY 139645 A MY139645 A MY 139645A MY PI20050501 A MYPI20050501 A MY PI20050501A MY PI20050501 A MYPI20050501 A MY PI20050501A MY 139645 A MY139645 A MY 139645A
- Authority
- MY
- Malaysia
- Prior art keywords
- inflammatory
- disorders
- pain
- vascular
- general
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 2
- 102000011040 TRPV Cation Channels Human genes 0.000 title 1
- 108010062740 TRPV Cation Channels Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 abstract 5
- 208000004454 Hyperalgesia Diseases 0.000 abstract 4
- 208000002193 Pain Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000002496 gastric effect Effects 0.000 abstract 3
- 230000036407 pain Effects 0.000 abstract 3
- 208000035154 Hyperesthesia Diseases 0.000 abstract 2
- 206010065390 Inflammatory pain Diseases 0.000 abstract 2
- 206010053552 allodynia Diseases 0.000 abstract 2
- 208000004296 neuralgia Diseases 0.000 abstract 2
- 208000021722 neuropathic pain Diseases 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 208000001387 Causalgia Diseases 0.000 abstract 1
- 208000006561 Cluster Headache Diseases 0.000 abstract 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000009889 Herpes Simplex Diseases 0.000 abstract 1
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- -1 PYRIMIDINE ETHERS Chemical class 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 206010043269 Tension headache Diseases 0.000 abstract 1
- 208000008548 Tension-Type Headache Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 206010047642 Vitiligo Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000029162 bladder disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000018912 cluster headache syndrome Diseases 0.000 abstract 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 abstract 1
- 208000000718 duodenal ulcer Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000003779 hair growth Effects 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004899 motility Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 231100000430 skin reaction Toxicity 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
- 230000009092 tissue dysfunction Effects 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 230000001457 vasomotor Effects 0.000 abstract 1
- 208000001319 vasomotor rhinitis Diseases 0.000 abstract 1
- 230000009278 visceral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54389604P | 2004-02-11 | 2004-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY139645A true MY139645A (en) | 2009-10-30 |
Family
ID=34860474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20050501A MY139645A (en) | 2004-02-11 | 2005-02-08 | Vanilloid receptor ligands and their use in treatments |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7511044B2 (https=) |
| EP (1) | EP1720868B1 (https=) |
| JP (1) | JP2007522235A (https=) |
| KR (1) | KR100813093B1 (https=) |
| CN (1) | CN1953976A (https=) |
| AR (1) | AR049771A1 (https=) |
| AT (1) | ATE447570T1 (https=) |
| AU (1) | AU2005212517B2 (https=) |
| BR (1) | BRPI0507927A (https=) |
| CA (1) | CA2555685A1 (https=) |
| DE (1) | DE602005017468D1 (https=) |
| EA (1) | EA010265B1 (https=) |
| ES (1) | ES2333973T3 (https=) |
| IL (1) | IL177369A0 (https=) |
| MY (1) | MY139645A (https=) |
| NO (1) | NO20064055L (https=) |
| TW (1) | TWI295670B (https=) |
| WO (1) | WO2005077944A1 (https=) |
| ZA (1) | ZA200607518B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006006740A1 (ja) * | 2004-07-14 | 2006-01-19 | Japan Tobacco Inc. | ３−アミノベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤 |
| MX2007000480A (es) | 2004-07-15 | 2007-03-29 | Japan Tobacco Inc | Compuesto de benzamida fusionado e inhibidor de actividad de receptor de vainilloide 1. |
| US7301022B2 (en) | 2005-02-15 | 2007-11-27 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| EP1967519B1 (en) * | 2005-12-28 | 2012-09-05 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity |
| US7906508B2 (en) * | 2005-12-28 | 2011-03-15 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity |
| BRPI0818003A2 (pt) * | 2007-10-18 | 2019-09-24 | Novartis Ag | inibidores de csf-1r, composições e métodos de uso |
| US7905954B2 (en) * | 2008-03-07 | 2011-03-15 | Xerox Corporation | Nanosized particles of benzimidazolone pigments |
| US8025723B2 (en) | 2008-03-07 | 2011-09-27 | Xerox Corporation | Nonpolar liquid and solid phase change ink compositions comprising nanosized particles of benzimidazolone pigments |
| US7985290B2 (en) | 2008-03-07 | 2011-07-26 | Xerox Corporation | Nonpolar liquid and solid phase change ink compositions comprising nanosized particles of benzimidazolone pigments |
| US7938903B2 (en) * | 2008-03-07 | 2011-05-10 | Xerox Corporation | Nanosized particles of benzimidazolone pigments |
| US7857901B2 (en) * | 2008-03-07 | 2010-12-28 | Xerox Corporation | Nonpolar liquid and solid phase change ink compositions comprising nanosized particles of benzimidazolone pigments |
| US8012254B2 (en) | 2008-03-07 | 2011-09-06 | Xerox Corporation | Nanosized particles of benzimidazolone pigments |
| US7883574B2 (en) | 2008-03-07 | 2011-02-08 | Xerox Corporation | Methods of making nanosized particles of benzimidazolone pigments |
| HRP20131069T1 (hr) | 2008-06-16 | 2013-12-20 | Merck Patent Gmbh | Derivati kinoksalindiona |
| EP2416766B1 (en) | 2009-04-09 | 2014-04-09 | Symrise AG | Compositions comprising trans-tert-butyl cyclohexanol as skin irritation-reducing agent |
| US8362270B2 (en) | 2010-05-11 | 2013-01-29 | Xerox Corporation | Self-assembled nanostructures |
| US8703988B2 (en) | 2010-06-22 | 2014-04-22 | Xerox Corporation | Self-assembled nanostructures |
| EP2322512B1 (en) | 2009-10-19 | 2015-10-21 | Xerox Corporation | Alkylated benzimidazolone compounds and self-assembled nanostructures generated therefrom |
| KR102678074B1 (ko) * | 2012-05-17 | 2024-06-26 | 제넨테크, 인크. | 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법 |
| CN103923033B (zh) * | 2013-01-14 | 2015-11-18 | 天津药物研究院 | 具有抗胃溃疡作用的哌嗪类衍生物 |
| US10537552B2 (en) | 2015-05-05 | 2020-01-21 | Carafe Drug Innovation, Llc | Substituted 5-hydroxyoxindoles and their use as analgesics and fever reducers |
| CN111393380A (zh) * | 2018-07-09 | 2020-07-10 | 湖南博隽生物医药有限公司 | 一种用于治疗慢性炎性痛的辣椒素受体拮抗剂 |
| PY2311120A (es) * | 2022-03-01 | 2023-09-14 | Syngenta Crop Protection Ag | Compuestos herbicidas |
| CN120398870A (zh) * | 2024-01-31 | 2025-08-01 | 深圳晶蛋生物医药科技有限公司 | 一种苯并吗啉类化合物及其应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725600A (en) | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
| US5272167A (en) | 1986-12-10 | 1993-12-21 | Schering Corporation | Pharmaceutically active compounds |
| US5750532A (en) | 1986-12-10 | 1998-05-12 | Schering Corporation | Pharmaceutically active compounds |
| KR930702312A (ko) | 1990-08-31 | 1993-09-08 | 아만 히데아키 | 피리미딘 유도체 및 의약 |
| DK168780B1 (da) * | 1992-04-15 | 1994-06-06 | Celwave R F A S | Antennesystem samt fremgangsmåde til fremstilling heraf |
| IL118469A (en) | 1995-06-15 | 2000-08-13 | Tanabe Seiyaku Co | Naphthalene derivatives their preparation and intermediates thereof |
| PL324291A1 (en) | 1995-06-20 | 1998-05-11 | Du Pont | Anthropodicidal and fungicidal cyclic amides |
| ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
| EA001450B1 (ru) | 1996-05-01 | 2001-04-23 | Эли Лилли Энд Компани | Галогензамещенные ингибиторы протеинкиназы с |
| CA2266639A1 (en) | 1996-09-23 | 1998-03-26 | Rajeshwar Singh | 3,4-disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators |
| US5916887A (en) | 1996-09-23 | 1999-06-29 | National Research Council Of Canada | 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| KR20000057254A (ko) | 1996-11-26 | 2000-09-15 | 메리 이. 보울러 | 메틸 치환된 살진균제 및 살절지동물제 |
| WO1998023155A1 (en) | 1996-11-26 | 1998-06-04 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal cyclic amides |
| US5932590A (en) | 1996-12-05 | 1999-08-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2276081A1 (en) | 1996-12-30 | 1998-07-09 | Lekhanh O. Tran | Inhibitors of farnesyl-protein transferase |
| US6093737A (en) | 1996-12-30 | 2000-07-25 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| BR9812041B1 (pt) | 1997-09-05 | 2009-08-11 | processo para a preparação de derivados n-acilados (hetero) aromáticos da hidroxilamina. | |
| CA2260499A1 (en) | 1998-01-29 | 1999-07-29 | Sumitomo Pharmaceuticals Company Limited | Pharmaceutical compositions for the treatment of ischemic brain damage |
| EP1054882A1 (fr) | 1998-02-13 | 2000-11-29 | Aventis Pharma S.A. | Derives de systemes heterocycliques condenses, leur preparation, les compositions pharmaceutiques qui les contiennent |
| US6306866B1 (en) | 1998-03-06 | 2001-10-23 | American Cyanamid Company | Use of aryl-substituted pyrimidines as insecticidal and acaricidal agents |
| AR014975A1 (es) | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
| AU5574799A (en) | 1998-08-25 | 2000-03-14 | Ortho-Mcneil Pharmaceutical, Inc. | Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application |
| TR200102490T2 (tr) | 1999-02-24 | 2001-12-21 | F.Hoffmann-La Roche Ag | Fenil ve piridinil türevleri |
| GB9907683D0 (en) | 1999-04-06 | 1999-05-26 | Synphar Lab Inc | Substituted azetidin-2-ones as cysteine protease inhibitors |
| KR20020063837A (ko) | 1999-07-19 | 2002-08-05 | 시오노기세이야쿠가부시키가이샤 | 아실옥시메톡시카르보닐 측쇄를 갖는 삼환 화합물 |
| WO2001007401A1 (en) | 1999-07-23 | 2001-02-01 | Shionogi & Co., Ltd. | Tricyclic compounds and drug compositions containing the same |
| BR0012697A (pt) | 1999-07-23 | 2002-04-09 | Shionogi & Co | Inibidores da diferenciação de th2 |
| AU6936500A (en) | 1999-08-24 | 2001-03-19 | Regents Of The University Of California, The | Non-quinoline inhibitors of malaria parasites |
| US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| MXPA02002115A (es) | 1999-09-14 | 2002-10-31 | Abbott Lab | Compuestos de eter 3-pirrolidiniloxi-3'-piridilico, utiles para controlar la transmision sinaptica quimica. . |
| HUP0204272A3 (en) | 2000-01-18 | 2005-03-29 | Pfizer Prod Inc | Corticotropin releasing factor antagonists, pharmaceutical compositions containing them and their use |
| WO2001054503A1 (en) | 2000-01-28 | 2001-08-02 | Akkadix Corporation | Methods for killing nematodes and nematode eggs using 4-phenoxy-6-aminopyrimidine derivatives |
| KR20030009416A (ko) | 2000-04-04 | 2003-01-29 | 시오노기세이야쿠가부시키가이샤 | 고지용성 약물을 함유하는 유성 조성물 |
| AU2001244610A1 (en) | 2000-04-05 | 2001-10-23 | Shionogi And Co., Ltd. | Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| KR20030029878A (ko) | 2000-08-30 | 2003-04-16 | 다우 아그로사이언시즈 엘엘씨 | 살충제로서 유용한 화합물, 살비제로서 유용한 화합물 및,이들의 사용방법 및 제조방법 |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US20040067938A1 (en) | 2000-09-29 | 2004-04-08 | Penglie Zhang | Quaternary amines and related inhibitors of factor xa |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| WO2002050052A1 (en) | 2000-12-20 | 2002-06-27 | Syngenta Participations Ag | N-acyl aminoacetonitriles having pesticidal properties |
| CA2441733A1 (en) | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| WO2002080853A2 (en) | 2001-04-09 | 2002-10-17 | Bristol-Myers Squibb Company | Fused heterocyclic inhibitors of factor xa |
| EP1389616B1 (en) | 2001-04-27 | 2011-07-27 | Mitsubishi Tanabe Pharma Corporation | 3,4-Dihalobenzylpiperidine derivatives and their medical use |
| IL159811A0 (en) | 2001-07-13 | 2004-06-20 | Neurogen Corp | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| JP2005509606A (ja) | 2001-10-03 | 2005-04-14 | ファルマシア・コーポレーション | 凝血カスケードを選択的に阻害するのに有用な置換された多環式化合物のプロドラッグ |
| AU2002367752A1 (en) | 2001-10-03 | 2003-11-17 | Pharmacia Corporation | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| JP4303109B2 (ja) | 2001-10-04 | 2009-07-29 | メルク エンド カムパニー インコーポレーテッド | 代謝共役型グルタミン酸受容体−５のヘテロアリール置換テトラゾール調節剤 |
| WO2003041649A2 (en) | 2001-11-13 | 2003-05-22 | Merck Frosst Canada & Co. | Cyanoalkylamino derivatives as protease inhibitors |
| JP2005518371A (ja) | 2001-12-10 | 2005-06-23 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療に於けるこれらの使用 |
| MXPA04011472A (es) * | 2002-05-22 | 2005-02-14 | Amgen Inc | Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor. |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| AR041191A1 (es) * | 2002-08-08 | 2005-05-04 | Amgen Inc | Ligandos del receptor vanilloide y su uso en tratamientos |
| US7419984B2 (en) | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
| GB0226724D0 (en) | 2002-11-15 | 2002-12-24 | Merck Sharp & Dohme | Therapeutic agents |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
-
2005
- 2005-02-08 MY MYPI20050501A patent/MY139645A/en unknown
- 2005-02-11 DE DE602005017468T patent/DE602005017468D1/de not_active Expired - Fee Related
- 2005-02-11 JP JP2006553265A patent/JP2007522235A/ja not_active Withdrawn
- 2005-02-11 CA CA002555685A patent/CA2555685A1/en not_active Abandoned
- 2005-02-11 AR ARP050100490A patent/AR049771A1/es not_active Application Discontinuation
- 2005-02-11 CN CNA200580008675XA patent/CN1953976A/zh active Pending
- 2005-02-11 WO PCT/US2005/004378 patent/WO2005077944A1/en not_active Ceased
- 2005-02-11 EP EP05722962A patent/EP1720868B1/en not_active Expired - Lifetime
- 2005-02-11 ES ES05722962T patent/ES2333973T3/es not_active Expired - Lifetime
- 2005-02-11 AT AT05722962T patent/ATE447570T1/de not_active IP Right Cessation
- 2005-02-11 AU AU2005212517A patent/AU2005212517B2/en not_active Ceased
- 2005-02-11 BR BRPI0507927-6A patent/BRPI0507927A/pt not_active IP Right Cessation
- 2005-02-11 KR KR1020067018172A patent/KR100813093B1/ko not_active Expired - Fee Related
- 2005-02-11 EA EA200601426A patent/EA010265B1/ru not_active IP Right Cessation
- 2005-02-11 US US11/056,568 patent/US7511044B2/en not_active Expired - Fee Related
- 2005-02-14 TW TW094104222A patent/TWI295670B/zh active
-
2006
- 2006-08-08 IL IL177369A patent/IL177369A0/en unknown
- 2006-09-08 ZA ZA200607518A patent/ZA200607518B/en unknown
- 2006-09-08 NO NO20064055A patent/NO20064055L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005212517B2 (en) | 2009-05-21 |
| TWI295670B (en) | 2008-04-11 |
| AU2005212517A1 (en) | 2005-08-25 |
| US7511044B2 (en) | 2009-03-31 |
| CA2555685A1 (en) | 2005-08-25 |
| ATE447570T1 (de) | 2009-11-15 |
| IL177369A0 (en) | 2006-12-10 |
| EA010265B1 (ru) | 2008-06-30 |
| US20050176726A1 (en) | 2005-08-11 |
| KR20070033325A (ko) | 2007-03-26 |
| EP1720868B1 (en) | 2009-11-04 |
| ES2333973T3 (es) | 2010-03-03 |
| TW200534858A (en) | 2005-11-01 |
| AR049771A1 (es) | 2006-09-06 |
| CN1953976A (zh) | 2007-04-25 |
| EP1720868A1 (en) | 2006-11-15 |
| EA200601426A1 (ru) | 2007-02-27 |
| DE602005017468D1 (de) | 2009-12-17 |
| WO2005077944A1 (en) | 2005-08-25 |
| JP2007522235A (ja) | 2007-08-09 |
| ZA200607518B (en) | 2008-07-30 |
| KR100813093B1 (ko) | 2008-03-17 |
| NO20064055L (no) | 2006-10-24 |
| BRPI0507927A (pt) | 2007-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004014871A8 (en) | Vanilloid receptor ligands and their use in treatments | |
| MY139645A (en) | Vanilloid receptor ligands and their use in treatments | |
| PL375552A1 (en) | Vanilloid receptor ligands and their medical applications | |
| WO2005033105A3 (en) | Vanilloid receptor ligands and their use in treatments | |
| WO2005072681A3 (en) | Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain. | |
| NZ599431A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| WO2006047492A3 (en) | Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament | |
| MY193765A (en) | Sulfonylureas and related compounds and use of same | |
| NZ593684A (en) | Novel vanilloid receptor ligands and their use for producing medicaments | |
| UA94246C2 (ru) | Производные индазола, которые ингибируют рецептор trpv1 | |
| WO2011124923A3 (en) | Pyrazolyl ureas as p38 map kinase inhibitors | |
| NO20084729L (no) | Antagonister for vanilloidreseptor subtype 1 (VR1) og anvendelser derav | |
| WO2008156817A3 (en) | Renin inhibitors | |
| WO2009096996A8 (en) | Renin inhibitors | |
| AR073226A1 (es) | Forma polimorfica cristalina b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilamino-metil] benzamida | |
| WO2007117559A3 (en) | Renin inhibitors | |
| EP1688408A3 (en) | Vanilloid receptor ligands and their use in treatments | |
| EP1780211A3 (en) | Vanilloid receptor ligands and their use in treatments | |
| AU2021372512A9 (en) | Regimens for the treatment of hair loss disorders with deuterated jak inhibitors | |
| MX2010006331A (es) | Hidantoinas sustituidas como inhibidores de cinasa mek. | |
| EP1780196A3 (en) | Pyridine derivatives for use as vanilloid receptor ligands | |
| EA201000337A1 (ru) | Модулятор nrg1 для лечения респираторных расстройств | |
| IL190508A0 (en) | Fluorinated compounds and pharmaceutical compositions containing the same | |
| NO20090972L (no) | Pyrazolo[1,5-A]pyrimidiner, fremgangsmater, anvendelser og sammensetninger | |
| WO2021021953A3 (en) | Dopamine receptor d1 agonists and methods of use |